Omega-3 fatty acid supplementation is associated with favorable outcomes in patients with sepsis: an updated meta-analysis

Wang, Chenyang; Han, Dawei; Feng, Xiaojing; Wu, Jing

doi:10.1177/0300060520953684

Cited by 16 publications

(12 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wang et al. ( 2020 ) illustrated that supplementation with ω-3 PUFAs could reduce mortality in patients with sepsis, along with shortening the duration spent in ICU. Tian et al.…”

Section: Discussionmentioning

confidence: 99%

Protective effect of omega-3 polyunsaturated fatty acids on sepsis via the AMPK/mTOR pathway

Liu

et al. 2023

Pharmaceutical Biology

View full text Add to dashboard Cite

Context Sepsis is a systemic inflammatory response caused by infection, with high morbidity and mortality. Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) have reported biological activities. Objective This study explored the signaling pathways through which ω-3 PUFAs protect against sepsis-induced multiorgan failure. Materials and methods Septic Sprague-Dawley (SD) rat model was established by the cecum ligation perforation (CLP) method. Rats were divided into control, sham, model, parenteral ω-3 PUFAs (0.5 g/kg) treatment, ω-3 PUFAs (0.5 g/kg) + AMPK inhibitor Compound C (30 mg/kg) treatment, and ω-3 PUFAs (0.5 g/kg) + mTOR activator MHY1485 (10 mg/kg) treatment groups. The serum inflammatory cytokines were measured using ELISA. Organ damage-related markers cTnI, CK, CK-MB, Cr, BUN, ALT, and AST were measured using an automated chemical analyzer. The AMPK/mTOR pathway in liver, kidney, and myocardial tissues was detected using western blot and qRT-PCR methods. Results CLP treatment enhanced the secretion of pro-inflammatory cytokines and multi-organ related markers, along with increased p-AMPK/AMPK ratio (from 0.47 to 0.87) and decreased p-mTOR/mTOR ratio (from 0.33 to 0.12) in rats. The inflammation response and multi-organ injury induced by CLP treatment could be partially counteracted by 0.5 g/kg parenteral ω-3 PUFA treatment. The activated AMPK/mTOR pathway in CLP-induced rats was further promoted. Finally, Compound C and MHY1485 could reverse the effects of parenteral ω-3 PUFA treatment on sepsis rats. Discussion and conclusion ω-3 PUFAs ameliorated sepsis development by activating the AMPK/mTOR pathway, serving as a potent therapeutic agent for sepsis. Further in vivo studies may validate potential clinical use.

show abstract

“…Wang et al. ( 2020 ) illustrated that supplementation with ω-3 PUFAs could reduce mortality in patients with sepsis, along with shortening the duration spent in ICU. Tian et al.…”

Section: Discussionmentioning

confidence: 99%

Protective effect of omega-3 polyunsaturated fatty acids on sepsis via the AMPK/mTOR pathway

Liu

et al. 2023

Pharmaceutical Biology

View full text Add to dashboard Cite

show abstract

“…The current nutrition guidelines recommend diets rich in anti-inflammatory lipids, such as omega-3 FAs, for patients with ARDS [ 14 ]. Furthermore, EPA and DHA were associated with reduced mortality in patients with sepsis, especially those with gastrointestinal dysfunction [ 55 ], and formulas enriched with omega-3 were strongly recommended by ESPEN [ 18 ]. The selenium intake was also below the proposed DRIs levels; selenium is required for the synthesis of the amino acid selenocysteine, an essential component of at least 25 selenoproteins, with antioxidant and redox activity in human tissues.…”

Section: Discussionmentioning

confidence: 99%

Factors Associated with Interruptions of Enteral Nutrition and the Impact on Macro- and Micronutrient Deficits in ICU Patients

et al. 2023

View full text Add to dashboard Cite

Background and Aim: Feeding interruptions in critical care patients are often unjustified. We aimed to determine the causes, duration, and frequency of enteral nutrition interruptions (ENIs) and to assess macronutrients and antioxidant deficits according to European Society of Parenteral Enteral Nutrition (ESPEN) guidelines. Methods: We prospectively enrolled Intensive Care Unit (ICU) patients admitted for more than 48 h with an inability to orally eat from April to December 2019. The type of enteral nutrition, the number of calories administered, the time of feeding initiation, the reasons for delaying feeding, and the causes for ENI were recorded. Results: 81 patients were enrolled, with a median duration of ENIs of 5.2 (3.4–7.4) hours/day. Gastric residual volume (GRV) monitoring—a highly controversial practice—was the most common cause of ENI (median duration 3 (2.3–3) hours/day). The mean energy intake was 1037 ± 281 kcal/day, while 60.5% of patients covered less than 65% of the total energy needs (1751 ± 295 kcal/day, according to mean Body Mass Index (BMI)). The median daily protein intake did not exceed 0.43 ± 0.3 gr/kg/day of the actual body weight (BW), whereas ESPEN recommends 1.3 gr/kg/day for adjusted BW (p < 0.001). The average administration of micronutrients and antioxidants (arginine, selenium, zinc, vitamins) was significantly less than the dietary reference intake (p < 0.01). Conclusion: ENIs lead to substantial caloric, protein, and antioxidant deficits.

show abstract

“…Hereunder we review the data that might support this hypothesis. A number of meta-analyses of relevant trials of omega-3 PUFAs have been published recently [34 ▪ ,35 ▪ ,36,37]. Pradelli et al [34 ▪ ] reviewed 49 randomized controlled trials (RCTs) comparing omega-3 PUFA enriched PN with standard (nonomega-3 PUFA enriched) PN in adult hospitalized patients.…”

Section: Omega-3 Polyunsaturated Fatty Acids and Sepsismentioning

confidence: 99%

The role of omega-3 polyunsaturated fatty acids in the intensive care unit

Singer¹,

Calder

2023

Current Opinion in Clinical Nutrition &Amp; Metabolic Care

View full text Add to dashboard Cite

Purpose of reviewThis review provides an update on the actions of omega-3 polyunsaturated fatty acids (PUFAs) and presents the most recent findings from trials in patients in the intensive care unit (ICU) setting including relevant meta-analyses. Many specialized pro-resolving mediators (SPMs) are produced from bioactive omega-3 PUFAs and may explain many of the beneficial effects of omega-3 PUFAs, although other mechanisms of action of omega-3 PUFAs are being uncovered. Recent findingsSPMs resolve inflammation, promote healing and support antiinfection activities of the immune system. Since publication of the ESPEN guidelines, numerous studies further support the use of omega-3 PUFAs. Recent meta-analyses favor the inclusion of omega-3 PUFAs in nutrition support of patients with acute respiratory distress syndrome or sepsis. Recent trials indicate that omega-3 PUFAs may protect against delirium and liver dysfunction in patients in the ICU, although effects on muscle loss are unclear and require further investigation. Critical illness may alter omega-3 PUFA turnover. There has been significant discussion about the potential for omega-3 PUFAs and SPMs in treatment of coronavirus disease 2019.

show abstract

Omega-3 fatty acid supplementation is associated with favorable outcomes in patients with sepsis: an updated meta-analysis

Cited by 16 publications

References 42 publications

Protective effect of omega-3 polyunsaturated fatty acids on sepsis via the AMPK/mTOR pathway

Protective effect of omega-3 polyunsaturated fatty acids on sepsis via the AMPK/mTOR pathway

Factors Associated with Interruptions of Enteral Nutrition and the Impact on Macro- and Micronutrient Deficits in ICU Patients

The role of omega-3 polyunsaturated fatty acids in the intensive care unit

Contact Info

Product

Resources

About